Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Inclusion Criteria: * on stable doses (more than 3 months) of antihyperglycemic agents (except for an SGLT2 inhibitor and insulin) * have an A1c ≥7% and ≤11% * Estimated glomerular filtration rate (eGFR) must be ≥45 ml/min•1.73 m2 * have an NT-proBNP ≥500 pg/mL * be on a stable dose of guideline-directed HF medication (i.e., angiotensin converting enzyme \[ACE\] inhibitor, angiotensin II receptor blocker \[ARB\], or angiotensin receptor neprilysin inhibitor \[ARNI\], β-blocker, diuretics, and/or mineralcorticoid receptor antagonist) for at least 4 weeks * be on stable antihypertensive therapy for at least 2 months Exclusion Criteria: * T1DM * repeated fasting plasma glucose (FPG) or fasting self-monitored blood glucose measurements ≥240 mg/dL or both * during the pretreatment phase, NYHA Class IV HF status, uncontrolled hypertension as defined as systolic blood pressure (SBP) \>160 or diastolic blood pressure (DBP) \>100 mmHg * liver disease (ALT or AST \>3 x ULN) * anemia Hb\<10 * anticipated cardiac surgery or coronary intervention within the next 3 months * severe unremediated valvular heart disease * major CV event (e.g., MI, cerebrovascular accident) within 3 months prior to screening visit * hospitalization for HF within 2 months prior to screening visit * documented atrial fibrillation * history of atraumatic amputation within past 12 months of screening or critical ischemia of the lower extremity within 6 months of screening * an active skin ulcer, osteomyelitis, or gangrene * have an allergy to iodocyanine green and inulin